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Objectives: P-selectin inhibition has been found to limit venous thrombosis. We hypothesize that elevated levels of
P-selectin will amplify thrombosis, mediated by procoagulant microparticles (MPs).
Methods: Male mice (Mus musculus, n659), 20 to 25 grams, underwent IVC ligation to induce thrombosis. Groups
consisted of wild type (WT) C57BL/6 controls, mice with high circulating levels of soluble P-selectin (^CT), P-selectin
gene-interrupted knockout mice (PKO), and E- and P-selectin gene-interrupted mice (EPKO). Additional groups were
used to evaluate the ability of a P-sel antagonist (rPSGL-Ig) and an antibody directed against PSGL-1 to downregulate
the effects of P-sel in ^CT mice and WT mice administered soluble P-sel at time of thrombosis. Animals were sacrificed
on days 2 and 6 after IVC ligation. Thrombus mass (TM), vein wall morphometrics, and serum leukocyte/platelet
microparticles (MPs) were evaluated by means of double-stained fluorescence-activated cell scanning analysis, and soluble
P- and E-sel protein determination by ELISA.
Results: At days 2 and 6 in phase I of the experiment, significant differences (P < .01) in TM were noted between groups,
with ^CT animals having the largest thrombi (50% and 57% increase in TM compared to WT at days 2 and 6) while EPKO
mice had the smallest thrombi. Statistically, greater levels of neutrophils and total inflammatory cells were noted in the
vein walls of ^CT animals at day 2 compared with WT and PKO animals. A significant difference was noted between ^CT
and EPKO for neutrophils, monocytes, and total inflammatory cells, also at day 2. At day 6, the only statistically
significant difference was found for monocytes, with a higher number in the ^CT animals than in WT animals. The
evaluation of MPs revealed that the ^CT mice had a mixed leukocyte (MAC-1) and platelet (CD41) MP population that
was also present in WT and PKO mice on day 2 and day 6. EPKO mice revealed a primarily platelet-derived MP
population. Of interest, the ^CT mice with the highest TM showed a high amount of mean channel fluorescence for
MAC-1 (phycoerythrin) antibody, indicative of leukocyte MPs. ^CT mice revealed statistically higher levels of soluble
P-selectin at days 2 and 6. In phase 2, an antibody directed against PSGL-1 was more effective than rPSGL-Ig in
decreasing TM and limiting leukocyte-derived MP fluorescence.
Conclusions: This study demonstrates that high circulating levels of P-selectin are associated with increased thrombosis,
whereas a lack of P-selectin and E-selectin is associated with a lessening of thrombosis. Additionally, leukocyte MPs are
associated with venous thrombus formation. These data suggest the importance of selectins to venous thrombogenesis
and show that P-selectin and leukocyte-derived MPs should be good targets to limit venous thrombus formation. (J Vasc
Surg 2003;38:1075-89.)
P-selectin augments vein wall inflammation and pro-
motes thrombus generation when stimulated by a throm-
botic stimulus. The adhesion molecule P-selectin—which is
present in platelet -granules and endothelial cell Weibel-
Palade bodies1 and is responsible for leukocyte rolling—is
upregulated early during venous thrombosis, promoting
vein wall inflammation in multiple animal models.2 Block-
ing P-selectin expression, both by a receptor antagonist or
antibody approach, decreases thrombosis, facilitates
thrombolysis, and decreases vein wall inflammation.3-5 Ad-
ditionally, E-selectin, which temporally follows P-selectin
upregulation, has been found to augment the thrombotic
response in a model of venous thrombosis and to amplify
the effects of P-selectin.2 Our hypothesis is that venous
thrombus formation in the presence of high circulating
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levels of P-selectin should result in an enhancement of both
the thrombotic and inflammatory response.
Animals used in the current study include ^CT mice,
animals genetically engineered to express P-selectin with-
out its cytoplasmic domain.6,7 Mice expressing P-selectin
had gene deletions created in exons 13 and 14, which
encode for the necessary amino acids for the P-selectin
cytoplasmic tail (CT). Chimeric mice derived from embry-
onic stem cells with the mutated P-selectin gene were bred
onto a C57BL/6J female mouse background. Homozy-
gous ^CT mice have a normal phenotype and hematology
profile. The circulating plasma P-selectin expression in ^CT
mice is three to four times higher than in WT mice.6 We
likewise found a fourfold increase of soluble P-selectin
levels in the ^CT animals at day 2 and nearly a threefold
increase at day 6 compared with WT mice. The use of these
mice along with selectin-deficient animals provides an op-
portunity to determine the effect of selectins on venous
thrombogenesis. Mice gene-interrupted for P-selectin
(PKO) and for both E- and P-selectin (EPKO) showed
essentially no soluble circulating P-selectin at either time
point, confirming this phenotype. Doubly deficient mice
demonstrated no soluble E-selectin. Even PKO animals
revealed roughly a 40% to 55% decrease in E-selectin,
confirming the overlap in the selectin systems.
In previous studies, we have demonstrated that selec-
tins are upregulated after venous thrombosis in the mouse.2
At 6 hours and on day 2 after thrombosis, P-selectin mRNA
and protein is elevated in thrombosed vein walls versus
control vein walls. This correlates with an increase in vein
wall neutrophils. E-selectin (which usually follows tempo-
rally after P-selectin expression) is upregulated later with
mRNA elevations on day 2 after thrombosis and protein
elevations on day 6 after thrombosis. This correlates with
an increase in vein wall mononuclear cells. Animals genet-
ically modified to be deficient in both P- and E-selectin
demonstrated significantly lower thrombus weights com-
pared with control animals at both day 2 and day 6 after
thrombosis and significantly less fibrin staining in their
thrombi at the same time points.8 In a rat model, P-selectin
inhibition is associated with decreased vein wall collagen
noted 1 week after thrombus induction.9 Additional con-
firmation concerning the importance of selectins in venous
thrombosis comes from work in the cat and primate.10,11
P-selectin inhibition alone in a primate model of venous
thrombosis has also been found to treat venous thrombosis,
on both days 2 and 7 after thrombus formation that was
equivalent to that in animals treated with Fragmin (Pfizer,
Ann Arbor, Mich), without any anticoagulation effect.12
METHODS
Mouse IVC stasis model. Male mice (Mus musculus,
n659) weighing 20 to 30 grams were anesthetized, a mid-
line laparotomy was made, and the inferior vena cava (IVC)
directly approached and ligated with 7-0 Prolene suture
just below the renal veins with ligation of large venous side
branches.2 Mice were evaluated at selected time points after
IVC ligation, including day 2 and day 6. These time points,
which have been used in our previous natural history study,
allow for the analysis at both an early (acute) and later
(chronic) time. Data evaluation consisted of thrombus
mass (TM), vein wall morphometric analysis, plasma leuko-
cyte/platelet microparticles (MPs) by means of double-
stained fluorescence-activated cell scanning (FACS) analy-
sis, and plasma soluble P- and E-selectin protein
determination by ELISA.
Fig 1. Experimental protocol. WT, Wild type; ^CT, mice with high circulating levels of soluble P-selectin; PKO,
P-selectin gene-deleted mice; EPKO, double gene-deleted mice.
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A Phase I study involved groups consisting of the
following: true controls (n  44), which had no surgical
dissection around the IVC; shams (n  230) that had
surgical dissection around the IVC only; wild type (WT)
C57BL/6 controls (Harlan, Indianapolis, Ind); hyperco-
agulable mice with high levels of soluble P-selectin (^CT,
Wagner, Cambridge, Mass); P-selectin gene-deleted mice
(PKO, Jackson Labs, Bar Harbor, Me); and E/P-selectin
gene deleted mice (EPKO, Bullard, University of Alabama,
Birmingham, Ala).
A Phase II study involved mice treated just prior to
surgical ligation with various interventions. These included
Fig 2. Thrombus mass at day 2 and day 6 in shams, wild type mice (WT), mice with high circulating levels of soluble
P-selectin (^CT) mice, P-selectin gene-deleted mice (PKO), and double gene-deleted mice (EPKO). Shams included
WT, ^CT, and PKO groups. n, Number of animals per group.
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WT mice treated at time of surgery with supplemental P-
selectin (1.2g/g body weight), ^CT mice given a P-selectin
receptor antagonist (rPSGL-Ig, 10 mg/kg, Wyeth Research,
Cambridge Mass), WT mice supplemented with human sol-
uble P-selectin (1.2g/g body weight, Wyeth Research)
treated with the same rPSGL-Ig (10 mg/kg), and ^CT mice
treated with a specific antibody to PSGL-1 (Ab-PSGL-1, 2
mg/kg, Wyeth Research) (Fig 1). The doses of soluble P-
selectin and rPSGL-Ig have been used successfully in wild type
and ^CT mice by Andre et al.6 The dose of the antibody to
PSGL-1 was recommended as an effective dose in the mouse
by Wyeth Research. Animals sacrificed at day 2 received only
one dose of reagent, while animals sacrificed at day 6 also were
dosed only one time for P-selectin and Ab-PSGL-1, and those
treated with rPSGL-Ig received two doses of the compound
(day 0 and day 3). All WT mice in the combination groups
were treated with rPSGL-Ig first, then dosed with soluble
P-selectin.
Thrombus mass. Groups of mice (15-35 per group)
were analyzed for the different experimental conditions at
each time point. This technique is an indirect measure of
thrombus content. At sacrifice, the IVC was removed,
weighed (grams), and measured for length (cm). The
weight was then normalized to length (weight/length
measurement2).
Vein wall morphometrics. Standard methods for tis-
sue fixation with paraffin-embedded sections were used for
analysis. Veins were examined under high-power oil im-
mersion light microscopy. Sections from paraffin-embed-
ded tissues were stained with hematoxylin-eosin. Five rep-
resentative high-power fields (HPFs; oil immersion 1000)
were examined around the vein wall, and the cell count of the
vein wall was analyzed. Cells were identified as either neutro-
phils, monocyte/macrophages, or lymphocytes on the basis of
standard histologic criteria.13 Results from the 5 high-power
fields were added together for each section studied, and mean
 SE was calculated for each group.
Murine platelet and leukocyte microparticle analy-
sis. MPs, fragments of phospholipid cell membranes that
are hypercoagulable, have been found to modulate a num-
ber of inflammatory cell vessel wall interactions. Groups of
mice (4-10 per group) were analyzed for the different
experimental conditions at each time point. 500 L of
whole blood was removed from the mice by intracardiac
puncture. Platelet poor plasma (PPP) was obtained by
centrifuging blood at 1500g and 4°C for 25 minutes and
centrifuging again for 2 minutes at 15,000g to remove
contaminating cells from the plasma. PPP (200 L) obtained
from each mouse was diluted 1:3 with 600 L of 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
buffer. Additionally, 100 L of individual mouse plasma was
pooled and divided in three equal volumes and added to 600
L of HEPES buffer for internal controls. All samples were
centrifuged for 2 hours at 200,000g to separate MPs, and they
were resuspended in 120 L of HEPES buffer. Antibodies
that stained leukocytes and platelets that were added to sam-
ples included rat anti-murine PE (MAC-1, stains leukocytes)
10 g/mL (Chemicon International, Temecula, Calif) or
control rat PE IgG (BD Pharmingen, San Diego, Calif), and
rat anti-murine fluorescein isothiocyanate (FITC; CD41 Ab,
stains platelets) 5 g/mL (BD Pharmingen) or control rat
FITC IgG (BD Pharmingen). Murine antibody controls con-
sisted of the following: FITC/PE, 1.5 L/0.6 L (negative
control), leukocyte marker MAC-1 (PE), 12.0 L (positive
control), and platelet marker FITC (CD41), 1.2 L (positive
control). Test samples and antibodies were then mixed and
incubated on ice for 20 minutes. Samples were centrifuged for
1 hour at 200,000g, washed with phosphate buffered saline
(PBS), fixed with 0.5% paraformaldehyde, and stored at 4°C
for FACS analysis. Flow cytometry analysis was performed by
the Biomedical Research Core Facilities (University of Mich-
igan Medical Center, Ann Arbor, Mich), on a Becton Dickin-
son FACS Vantage SE cell sorter with Cell Quest (MAC
platform; Becton Dickinson, Franklin Lakes, NJ) using for-
ward versus side scatter to gate on MP populations.
Soluble P- and E-selectin sandwich ELISA. Groups
of mice (4-10 per group) were analyzed for the various
experimental conditions at each time point. Blood samples
were collected (300 L) in 0.1 L of acid citrate dextrose
and centrifuged immediately for 15 minutes at 1000g.
Plasma was collected and centrifuged again at 16,000g for
10 minutes. Mouse soluble P-selectin (sP-selectin) and
soluble E-selectin (sE-selectin) immunoassays were pur-
chased as kits (Quantikine M; R&D Systems, Inc, Minne-
apolis, Minn), and the assays were performed as described
in the manufacturer’s manual.
Statistical evaluation and animal use. Statistical
analysis included mean  SEM, analysis of variance
(ANOVA), nonparametric Spearman  correlation, and
unpaired Student t tests for parametric data. Significance
was defined as P  .05. Comparisons between individual
groups were run if the overall ANOVA was significant
between all groups. Sham values are shown in the figures,
but are not discussed in the text. All rats were housed and
cared for by the University of Michigan Unit for Labora-
tory Animal Medicine. The University of Michigan is an
Association for Assessment and Accreditation of Labora-
tory Animal Care International–accredited facility under
the direction of a veterinarian according to the “Principles
of Laboratory Animal Care” (formulated by the National
Society for Medical Research) and Guide for the Care and
Use of Laboratory Animals (National Academy of Sciences,
1996). The University of Michigan Committee on Use and
Care of Animals approved this research protocol.
RESULTS
Phase I
Delta-CT mice generate significantly more throm-
bus than wild type mice. ^CT mice demonstrated a 50%
increase in TM compared with WT at day 2 (P .01), and
a 57% increase on day 6 (P .01) (Fig 2). Although
thrombus was noted in 53/59 (90%) of WT mice, all ^CT
mice (57/57, 100%) demonstrated thrombus formation.
Group comparisons showed that ^CT mice had a statisti-
cally significant increase in TM at day 2 (P .01) compared
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Fig 3. Morphometric evaluation of inflammatory cells in the vein wall at day 2 and day 6 in shams, wild type (WT) mice,
mice with high circulating levels of soluble P-selectin (^CT) mice, P-selectin gene-deleted mice (PKO), and double
gene-deleted mice (EPKO). Shams included WT, ^CT, and PKO groups. n, Number of animals per group; neut,
neutrophils; mono, monocytes; TC, total inflammatory cells.
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with all groups, and a statistically significant increase com-
pared with all groups except PKO at day 6 (P .01). PKO
animals demonstrated a nonsignificant decrease in TM at
day 2 only (7%) with an actual increase in TM at day 6 (39%
above WT) and EPKO showed a nonsignificant decrease in
TM at days 2 and 6 (16% and 15%, respectively). However,
when evaluating only those animals with the presence of
IVC thrombus (TM 	 52  10-4 g/cm, or 2 standard
deviations above sham plus control level), there was a 20%
decrease in TM in EPKO compared with WT controls at
day 2 and a significant 26% decrease in TM at day 6 in
EPKO compared with WT controls (182  15  10
4
g/cm vs 246  26  10
4 g/cm, P  .05).
Greater inflammation in the vein wall with P-select-
in. Morphometric evaluation of the vein wall showed sta-
tistically more neutrophils (75  15 vs 42  3 cells/5
HPFs, P  .05) and total inflammatory cells (100  15 vs
58  5 cells/5 HPFs, P  .01) in the vein walls of ^CT
Fig 4. Fluorescence-activated cell scanning analysis with negative controls located on the left, and study specimens on
the right. Shown is a representative example of each group at day 2 (A) and day 6 (B) in wild type (WT) mice, mice with
high circulating levels of soluble P-selectin (^CT) mice, P-selectin gene-deleted mice (PKO), and double gene-deleted
mice (EPKO).
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animals at day 2 than in WT animals. Statistical differences
were also found between ^CT and PKO animals at day 2 for
both neutrophils (75  15 vs 38  5 cells/5 HPFs, P 
.05) and total inflammatory cells (100  15 vs 62  6
cells/5 HPFs, P  .05). Also noted at day 2, there was a
significant difference between ^CT and EPKO mice for
neutrophils (75  15 vs 27  6 cells/5 HPFs, P  .05)
andtotal inflammatory cells (100  15 vs 42  5 cells/5
HPFs, P  .05). At day 6, the only statistically significant
difference was found for monocytes, with greater numbers
in the ^CT animals than in WT animals and greater num-
bers in EPKO than in PKO or WT animals (P  .05 and P
 .01, respectively) (Fig 3).
Leukocyte microparticles are increased in ^CT mice
and decreased in EPKO mice. WT, ^CT, and PKO mice
demonstrated a doubly labeled leukocyte (MAC-1)- and
platelet (CD41)-derived MP population on day 2 and day
6. In contrast, EPKO mice demonstrated primarily a plate-
let-derived, along with a smaller leukocyte-derived, MP
population. This paralleled a significant decrease in TM in
the EPKO mice when compared with controls at both time
points (Fig 4).
Fig 4. (Continued.)
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The evaluation of mean channel fluorescence (which is
an indication of intensity of MAC-1 [leukocyte] or CD41
[platelet] staining), revealed the ^CT mice to have the
highest leukocyte fluorescence at both time points. This
correlated with the ^CT group having the highest TM. The
EPKO mice had the lowest leukocyte fluorescence at both
time points, correlating with their lowest TM. Notably,
platelet fluorescence did not correlate with TM. At day 2,
the group with the highest TM (the ^CT group) did not
have the highest platelet fluorescence. Likewise, at day 6
the group with the lowest TM (EPKO) did not have the
lowest platelet fluorescence (Table I).
Fig 5. Soluble P-selectin levels at day 2 and day 6 in sham mice, wild type (WT) mice, mice with high circulating levels
of soluble P-selectin (^CT) mice, P-selectin gene-deleted mice (PKO), and double gene-deleted mice (EPKO). Shams
at day 2 include WT (6.01 ng/mg), ^CT (27.6 ng/mg), and PKO (0 ng/mg); shams at day 6 include WT (7.8
ng/mg), ^CT (27.2 ng/mg), and PKO (0 ng/mg). n, Number of animals per group.
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Soluble P-selectin is significantly elevated in ^CT
animals. ^CT animals revealed statistically significant ele-
vations of soluble P-selectin protein compared with all
groups at day 2 (P .01) and day 6 (P .05) (Fig 5). PKO
and EPKO animals revealed essentially no soluble P-selec-
tin at either time point. Statistically significant differences
were also noted between WT animals and PKO and EPKO
animals at both time points (P  .01).
Table I. Platelet (CD41)-and leukocyte (MAC-1)-derived microparticle populations (Phase I)
Mean channel fluorescence
Day 2 Platelet Leukocyte Day 6 Platelet Leukocyte
WT 153  36 97  45 WT 104  10 185  18
^CT 762  57 2263  113 ^CT 762  57 1189  162
PKO 1145  231 1762  210 PKO 301  15 211  15
EPKO 73  6 30  3 EPKO 238  24 36  3
WT, Wild type; ^CT, mice with high circulating levels of soluble P-selectin; PKO, P-selectin gene-deleted; EPKO, double gene-deleted.
Fig 6. Soluble E-selectin levels at day 2 and day 6 in sham mice, wild type (WT) mice, mice with high circulating levels
of soluble P-selectin (^CT) mice, P-selectin gene-deleted mice (PKO), and double gene-deleted mice (EPKO). Shams
at day 2 include WT (1284 pg/mg), ^CT (1023 pg/mg), and PKO (567 pg/mg); shams at day 6 include WT (1688
pg/mg), ^CT (1189 pg/mg), and PKO (615 pg/mg). n, Number of animals per group.
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^CT animals revealed statistically significant elevations of
soluble E protein compared with PKO and EPKO animals at
day 2 (P .01) and EPKO at day 6 (P .01) (Fig 6). PKO
animals demonstrated significantly reduced levels of E-selectin
at day 2 compared with WT (P  .01) and nonsignificant
reduced levels at day 6 (1073 218 vs 706 64 pg/mg total
protein; P  .15, ns). EPKO animals revealed no soluble
E-selectin at either time point (compared with WT, P  .01
and P .05, days 2 and 6 respectively).
Phase II
Thrombus mass decreased by Ab-PSGL-1 and not
rPSGL-Ig in ^CT mice. The increase in TM in ^CT
animals was not decreased at all by using rPSGL-Ig at either
time point (all treated ^CT animals demonstrated thrombus
at both time points). However, the mouse-specific Ab-
PSGL-1 was more effective in decreasing TM in ^CT mice
(towards the level of TM noted in WT animals), especially at
day 6. All treated ^CT animals (69/69, 100%) demonstrated
thrombus at both time points (Fig 7). Differences between
^CT and ^CT Ab-PSGL-1 were not significant at day 6.
WT animals treated with soluble P-selectin revealed a
15% increase above WT at day 2 (P  .3, ns) and a 21%
increase above WT at day 6 (P .15, ns), both less than the
increases demonstrated in Phase 1 for ^CT animals (50%
and 57%, respectively). rPSGL-Ig brought these levels to
below WT levels at both time points (significant decrease at
day 6, P  .05).
Fig 7. Thrombus mass analysis at day 2 and day 6 in wild type mice (WT), mice with high circulating levels of soluble
P-selectin (^CT), ^CT rPSGL-Ig mice, ^CT Ab-PSGL-1 mice, WT P-selectin (Psel) mice, and WT P-selectin
 rPSGL-Ig mice. WT  P-selectin mice had a 15% increase in thrombus mass above WT mice at day 2 and a 21%
increase in TM above WT mice at day 6. n, Number of animals per group.
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rPSGL-Ig and not Ab-PSGL-1 decreases vein wall
leukocyte extravasation. Morphometric evaluation of the
vein wall in ^CT mice revealed that rPSGL-Ig statistically
decreased both neutrophils (73  12 down to 22  6
cells/5 HPFs, P  .01) and total inflammatory cells (97 
12 down to 40  6 cells/5 HPFs, P  .01) at day 2.
However, Ab-PSGL-1 did not produce a similar statistically
significant decrease. No significant decrease was found for
either compound at day 6. Likewise, no significant differ-
ences were noted in vein wall inflammatory cell extravasa-
tion with either the addition of P-selectin to WT mice or
rPSGL-Ig to WT  P-selectin treated mice.
Ab-PSGL-1 and not rPSGL-Ig decreases leukocyte
microparticles. The addition of the Ab-PSGL-1 to ^CT
mice shifted their mixed leukocyte- and platelet-derived
MP population to a dominant platelet-derived MP popula-
tion on days 2 and 6. The addition of soluble P-selectin to
WT animals initiated the shift from a mixed leukocyte- and
platelet-derived MP population noted in Phase I, to a
predominately platelet-derived MP population at both time
points. ^CT mice given rPSGL-Ig shifted from a mixed MP
population on day 2, to a dominant platelet-derived MP
population on day 6 only (Fig 8).
Concerning mean channel fluorescence, leukocyte-de-
rived MP levels in ^CT plus Ab-PSGL-1 treated animals
were lower than in ^CT plus rPSGL-Ig. This correlates
with Ab-PSGL-1 having a greater effect on TM than
rPSGL-Ig. Furthermore, the addition of P-selectin to WT
mice markedly increased fluorescence for platelet-derived
MPs. This is consistent with supplemental P-selectin acti-
vating platelets (Table II).
Soluble selectin levels and selectin inhibition. Soluble
P-selectin levels in ^CT animals were slightly decreased by
rPSGL-Ig at day 2 (33 2 to 28 4 ng/mg total protein,
ns) with no decrease at day 6 (24  5 to 32  2, ng/mg
total protein, ns). However, Ab-PSGL-1 did result in a
statistically significant decline at day 2 (33 2 to 23  1
ng/mg total protein, P .01) and a lesser decline at day 6
(33 2 to 26 2 ng/mg total protein, ns). Similar results
were noted with soluble E-selectin levels with a statistically
significant decline at day 2 with Ab-PSGL-1 (1365  111
to 675 87 ng/mg total protein, P .01). Supplemental
P-selectin in WT animals resulted in no measurable increase
in levels of soluble P-selectin at day 2 or day 6 (Table III),
and only a slight elevation in soluble E-selectin levels at day
6 (P  .09, ns).
DISCUSSION
Our data would suggest that MPs, which are prothrom-
botic likely by virtue of tissue factor on their surface,14-18
are extremely important in early venous thrombogenesis,
especially those MPs derived from leukocytes. Most MP
data come from the arterial circulation and involve platelet-
derived MPs.19-26 The MPs’ thrombotic potential includes
the modulation of monocyte-endothelial cell adhesion,27
smooth muscle cell mitogenesis,28 and leukocyte aggrega-
tion and accumulation on selectin-expressing surfaces.29
Platelet-derived MPs are also involved in venous thrombo-
sis in the syndrome of heparin-induced thrombocytope-
nia.30
Less is known regarding leukocyte-derived MPs, al-
though two studies suggest that these MPs are associated
with endothelial cell activation and cytokine gene induction
as indicated by elevations in interleukin 6, monocyte che-
motactic protein–1, tumor necrosis factor, and a factor Xa
procoagulant response mediated by C-Jun N-Terminal Ki-
nase 1 signaling pathway.31,32 MPs that were not differen-
tiated from their origin were found to impair endothelial
Table II. Platelet (CD41)- and leukocyte (MAC-1)-derived microparticle populations (Phase II)
Mean channel fluorescence
Day 2 Platelet Leukocyte Day 6 Platelet Leukocyte
^CTrPSGL-Ig 199  10 211  31 ^CTrPSGL-lg 3967  598 2359  48
^CTAb-PSGL-1 216  12 26  1 ^CTAb-PSGL-1 1357  9 170  15
WTP-sel 1238  307 281  94 WTP-sel 2801  244 460  11
WTPselrPSGL-lg 62  4 77  6 WTPselrPSGL-lg 561  93 1009  116
WT, Wild type; ^CT, mice with high circulating levels of soluble P-selection; PKO, P-selectin gene-deleted; EPKO, double gene-deleted.
Table III. Circulating soluble P-selectin and E-selectin blood levels (Phase II)
Soluble selectin levels (ng/mg total protein)
Day 2 P-selectin E-selectin Day 6 P-selectin E-selectin
^CT 33  2 1365  111 ^CT 24  5 1073  218
^CTrPSGL-lg 28  4 909  210 ^CTrPSGL-lg 32  2 1224  103
^CTAb-PSGL-1 23  1 675  87 ^CTAb-PSGL-1 26  2 742  41
WT 8  1 1506  149 WT 8  2 1168  313
WTP-sel 8  1 1296  180 WTP-sel 8  1 1487  120
WTP-selrPSGL-lg 7  1 1203  198 WTP-selrPSGL-lg 6  1 1102  146
^CT, Mice with high circulating levels of soluble P-selectin; WT, wild type; P-sel, P-selectin.
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cell nitric oxide transduction from endothelial cells.33 Ad-
ditionally, MPs derived from endothelial cells were found
to induce monocyte tissue factor antigen and mRNA re-
lease, partially dependent on the interaction of the firm
adhesion receptor ICAM-1, with its counter-receptor be-
ta-2 integrin.34
We did not statistically compare our MP data among
groups because the FACS analyses were not run on the
same day for the different groups and times. Nonetheless,
qualitative comparisons strongly suggest the importance of
leukocyte-derived MPs over platelet-derived MPs in venous
thrombogenesis. This is supported by the observations that
(1) the animals with the greater TM had a significant dual
population of leukocyte and platelet-derived MPs, whereas
the animals with the lowest TM (EPKO) had predomi-
nately platelet-derived MPs at both days 2 and 6; (2) the
animals with the greatest TM had the highest leukocyte-
derived MP fluorescence (^CT); (3) animals with the low-
est TM had the lowest leukocyte-derived MP fluorescence
(EPKO); and (4) ^CT mice plus Ab-PSGL-1 had lower
leukocyte-derived MP fluorescence as compared with ^CT
mice plus rPSGL-Ig, consistent with a greater decrease in
TM with the Ab-PSGL-1 treatment than with rPSGL-Ig
treatment. In support of their importance to thrombogen-
Fig 8. Fluorescence-activated cell scanning analysis with negative controls located on the left and study specimens on
the right. Shown is a representative example of each group at day 2 (A) and day 6 (B) in ^CT  rPSGL-Ig, ^CT 
Ab-PSGL-1 mice, WT  P-selectin, and WT  P-selectin  rPSGL-Ig. ^CT, Mice with high circulating levels of
soluble P-selectin; WT, wild type.
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esis, MPs have been found to be associated with hyperco-
agulability. This was reflected by the shortened recalcified
clotting times in ^CT mice compared with WT mice, which
reversed to normal with the addition of rPSGL-Ig.6 An-
other possibility is that microparticles might be influenced
by thrombus composition. The composition of the throm-
bus, although not evaluated in this study, will be investi-
gated in future studies. However, this possibility is less
likely because EPKO animals have high circulating leuko-
cyte counts, yet demonstrated low levels of leukocyte-
derived MPs.
Results from this study indicate that ^CT mice are
hypercoagulable as they generate greater TM, but they also
exhibit high levels of MPs. Of interest, these effects cannot
only be due to elevated levels of P-selectin because (1)
supplemental P-selectin in WT mice did not generate TM
to the levels noted in the ^CT mice, although this may
reflect the fact that these animals did not demonstrate high
circulating soluble P-selectin by ELISA or that the injected
P-selectin was of human origin; (2) the effects of the ^CT
animals were not reversed to the levels of TM seen in WT
mice by rPSGL-Ig administration, whereas rPSGL-Ig ad-
ministration did reverse the elevations in TM noted in WT
mice given supplemental P-selectin; and (3) Ab-PSGL-1
only partially reversed the effects on ^CT mice towards
levels of TM noted in WT animals. The lack of high levels of
soluble P-selectin in WT  P-selectin animals may not be
due to actual low circulating levels but instead may relate to
the injected P-selectin being bound to its cell receptor
binding sites and not available to the assay, or be due to the
Fig 8. (Continued.)
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fact that the injected human P-selectin has low homology
with murine P-selectin and would not be detected by the
mouse soluble P-selectin ELISA assay.
We consider the failure of rPSGL-Ig to decrease TM in
^CT mice to be related either to inadequate dosage, time of
dose, or species specificity (rPSGL-Ig is based on the struc-
ture of human and not murine PSGL-1), or to the ^CT
phenotype involving some factor other than P-selectin.
Further experiments to address this issue are certainly indi-
cated. For example, a recent study demonstrated that the
dosage of rPSGL-Ig in the mouse that inhibits leukocyte
rolling varies, as does the dosage that results in the inhibi-
tion of the murine chemokine KC. Nonetheless, low-dos-
age rPSGL-Ig (1mg/kg) was found to be anti-inflamma-
tory in the mouse.35 In the current study, rPSGL-Ig did
decrease the inflammatory cell extravasation into the vein
wall in ^CT animals, suggesting an appropriate response to
rPSGL-Ig and supporting a disconnect between thrombo-
sis and inflammatory cell extravasation (as we have noted in
previous results from our laboratory). The Ab-PSGL-1 was
more effective than rPSGL-Ig in reducing levels of soluble
P-selectin and E-selectin at both time points and was more
effective in inhibiting TM and leukocyte-derived MPs.
We hypothesize that with injury, stasis, or hypercoagu-
lability in the venous circulation, selectins are expressed on
the surface of endothelial cells and platelets. Interactions
between selectins and their leukocyte receptors stimulate
fibrin formation.36 Procoagulant MPs, derived more from
activated leukocytes and less from activated platelets, then
are recruited to the area of thrombosis,16 where they am-
plify coagulation via tissue factor and the extrinsic path-
way.6,16,17,37-39 The co-localization of fibrin, platelets, and
leukocytes in the developing thrombus16 and the impor-
tance of P-selectin–mediated leukocyte-platelet interac-
tions to the generation of tissue factor14,40,41 provide sup-
port for this hypothesis and point to the central role of
inflammation in venous thrombogenesis.
In conclusion, this study demonstrates that high circu-
lating levels of P-selectin are associated with increased
venous thrombosis, while a lack of P-selectin and E-selectin
is associated with a lessening of venous thrombosis. Addi-
tionally, leukocyte-derived MPs are associated with early
venous thrombus formation. These data suggest the impor-
tance of selectins to venous thrombogenesis and suggest
that P-selectin and leukocyte-derived MPs should be good
targets to limit venous thrombogenesis.
We would like to thank D. Keith Bishop, PhD, Keri L.
Csencsits, PhD, and Sherri C. Wood, BS, for their profes-
sional assistance in the area of flow cytometry.
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